Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

Y0000677

Bromocriptine mesilate for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Bromo-α-ergocryptine methanesulfonate salt, (+)-2-Bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′-18-trione methanesulfonate salt, (+)-Bromocriptine methanesulfonate salt, Bromocriptine mesylate salt

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C32H40BrN5O5 · CH4SO3
Número de CAS:
22260-51-1
Peso molecular:
750.70
Beilstein:
4115238
Número MDL:
MFCD00069218
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831091
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

bromocriptine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

formato

neat

temp. de almacenamiento

−20°C

cadena SMILES

CS(O)(=O)=O.[H][C@@]12Cc3c(Br)[nH]c4cccc(C1=CC(CN2C)C(=O)N[C@@]5(O[C@]6(O)N([C@@H](CC(C)C)C(=O)N7CCC[C@@]67[H])C5=O)C(C)C)c34

InChI

1S/C32H40BrN5O5.CH4O3S/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18;1-5(2,3)4/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39);1H3,(H,2,3,4)/t18?,23-,24+,25+,31-,32+;/m1./s1

Clave InChI

NOJMTMIRQRDZMT-NEKRQHSLSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Bromocriptine mesilate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Pictogramas

Exclamation markEnvironment
GHS07,GHS09

Palabra de señalización

Warning

Frases de peligro

H302,H410

Consejos de prudencia

P301 + P312 + P330

Clasificaciones de peligro

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

In Ki Kim et al.
BMB reports, 45(8), 482-487 (2012-08-25)
To identify the novel inhibitors of endoplasmic reticulum stress-induced cell death, we performed a high throughput assay with a chemical library containing a total of 3280 bioactive small molecules. Cyclosporine A and bromocriptine were identified as potent inhibitors of thapsigargiin-induced
Ana Lúcia Beltrame et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 29(3), 201-204 (2012-11-22)
The aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two
Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump.
Marco R Schroeter et al.
Clinical research in cardiology : official journal of the German Cardiac Society, 102(2), 155-157 (2012-07-26)
Laura D Ratner et al.
Endocrinology, 153(12), 5980-5992 (2012-11-03)
Female infertility is often associated with deregulation of hormonal networks, and hyperprolactinemia is one of the most common endocrine disorders of the hypothalamic-pituitary axis affecting the reproductive functions. We have shown previously that transgenic female mice overexpressing human chorionic gonadotropin
J Michael Gaziano et al.
Journal of the American Heart Association, 1(5), e002279-e002279 (2013-01-15)
Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration-approved treatment for type 2 diabetes mellitus (T2DM). A 3070-subject randomized trial demonstrated a significant, 40% reduction in relative risk among bromocriptine-QR-treated
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico